Ocuphire Pharma, Inc. financial data

Symbol
OCUP on Nasdaq
Industry
Pharmaceutical Preparations
Location
37000 Grand River Ave., Suite 120, Farmington Hills, MI
State of incorporation
DE
Fiscal year end
December 31
Former names
REXAHN PHARMACEUTICALS, INC. (to 11/9/2020), CORPORATE ROAD SHOW DOT COM INC (to 4/29/2005), FERRARO FRANK (to 4/29/2003)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.14K % +15.1%
Debt-to-equity 9.6 % -14.4%
Return On Equity -30.2 % -155%
Return On Assets -27.6 % -156%
Operating Margin -91.7 % -329%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.2M shares +24.7%
Common Stock, Shares, Outstanding 26M shares +23.8%
Entity Public Float 89.2M USD +140%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 25.8M shares +23.2%
Weighted Average Number of Shares Outstanding, Diluted 25.8M shares +23.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 16.4M USD -63.7%
General and Administrative Expense 13.4M USD +28.7%
Operating Income (Loss) -15.1M USD -183%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -14.1M USD -174%
Income Tax Expense (Benefit) 12K USD -96.2%
Net Income (Loss) Attributable to Parent -14.1M USD -176%
Earnings Per Share, Basic -0.53 USD/shares -154%
Earnings Per Share, Diluted -0.53 USD/shares -156%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.4M USD +3.58%
Accounts Receivable, after Allowance for Credit Loss, Current 1.36M USD +906%
Other Assets, Current 87K USD +93.3%
Assets, Current 44.8M USD +3.16%
Property, Plant and Equipment, Net 0 USD -100%
Assets 44.8M USD +3.15%
Accounts Payable, Current 634K USD -72.7%
Employee-related Liabilities, Current 427K USD +42.3%
Accrued Liabilities, Current 3.49M USD +1.51%
Liabilities, Current 4.2M USD -27.1%
Liabilities 4.2M USD -27.1%
Retained Earnings (Accumulated Deficit) -96.3M USD -17.2%
Stockholders' Equity Attributable to Parent 40.6M USD +7.78%
Liabilities and Equity 44.8M USD +3.15%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.72M USD -56.8%
Net Cash Provided by (Used in) Financing Activities 2.38M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares +66.7%
Common Stock, Shares, Issued 26M shares +23.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.4M USD +3.58%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 20.1M USD +13.3%
Deferred Tax Assets, Gross 20.1M USD +9.43%
Depreciation 4K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -14.1M USD -176%
Property, Plant and Equipment, Gross 25K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 12.8M USD -2.35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 137M USD +14.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 3.08M USD -2.16%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%